Skip to main content
SpringerLink
Log in
Book cover

Liver Anesthesiology and Critical Care Medicine pp 21–39Cite as

Chronic Liver Failure and Hepatic Cirrhosis

  • Chapter
  • First Online:

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

AASLD:

American Association for the Study of Liver Diseases

AH:

Alcoholic hepatitis

ATP:

Adenosine triphosphate

CDC:

Center for disease control

CTP:

Child-Turcotte-Pugh

ECM:

Extracellular matrix

HBV:

Hepatitis B virus

HCC:

Hepatocellular carcinoma

HCV:

Hepatitis C virus

HPS:

Hepatopulmonary syndrome

HRS:

Hepatorenal syndrome

HSC:

Hepatic stellate cell

HVPG:

Hepatic venous pressure gradient

IL:

Interleukin

MDF:

Maddrey discriminant function

MELD:

Model for end-stage liver disease

NAFLD:

Nonalcoholic fatty liver disease

NASH:

Nonalcoholic steatohepatitis

POPH:

Portopulmonary hypertension

PSE:

Portosystemic encephalopathy

PVT:

Portal venous thrombosis

SAAG:

Serum-ascites albumin gradient

SBP:

Spontaneous bacterial peritonitis

TGF:

Transforming growth factor

TIPS:

Transjugular intrahepatic portosystemic shunt

TLRs:

Toll-like receptors

TNF:

Tumor necrosis factor

USPSTF:

United States preventative services task force

References

  1. Heron M. Deaths: Leading Causes for 2014. Natl Vital Stat Rep. 2016;65:1–96.

    Google Scholar 

  2. Scaglione S, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690–6.

    Article  PubMed  Google Scholar 

  3. Graudal N, et al. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230(2):165–71.

    Article  CAS  PubMed  Google Scholar 

  4. Giarelli L, et al. Occurrence of liver cirrhosis among autopsies in Trieste. IARC Sci Publ. 1991;112:37–43.

    Google Scholar 

  5. Mokdad AH, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195–200.

    Article  CAS  PubMed  Google Scholar 

  6. Hsu CC, et al. Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage. Diabetes Care. 2012;35(11):2286–92.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Denniston MM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mellinger JL, et al. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2015;13(3):577–84. quiz e30

    Article  PubMed  Google Scholar 

  9. Younossi ZM, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1. quiz e60

    Article  PubMed  Google Scholar 

  10. Wong RJ, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.

    Article  PubMed  Google Scholar 

  11. Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.

    Article  PubMed  Google Scholar 

  12. Williams CD, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.

    Article  PubMed  Google Scholar 

  13. Bellentani S, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–61.

    Article  CAS  PubMed  Google Scholar 

  14. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5). https://doi.org/10.3390/ijms17050774.

    Article  CAS  PubMed Central  Google Scholar 

  15. Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61(5):1226–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1):307–28.

    Article  PubMed  Google Scholar 

  17. Teli MR, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987–90.

    Article  CAS  PubMed  Google Scholar 

  18. Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine. 1962;41:249–76.

    Article  CAS  PubMed  Google Scholar 

  19. Sorensen TI, et al. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 1984;2(8397):241–4.

    Article  CAS  PubMed  Google Scholar 

  20. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.

    Article  PubMed  Google Scholar 

  21. Blum HE. History and global burden of viral hepatitis. Dig Dis. 2016;34(4):293–302.

    Article  PubMed  Google Scholar 

  22. Chan SL, et al. Infection and cancer: the case of hepatitis B. J Clin Oncol. 2016;34(1):83–90.

    Article  CAS  PubMed  Google Scholar 

  23. Lavanchy D, Mark K. Global epidemiology of hepatitis B virus infection. In: Liaw Y-F, Zoulim F, editors. Hepatitis B virus in human diseases. Cham: Springer International Publishing; 2016.

    Google Scholar 

  24. Ott JJ, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.

    Article  CAS  PubMed  Google Scholar 

  25. Wasley A, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201.

    Article  PubMed  Google Scholar 

  26. McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98(1):39–54.

    Article  PubMed  Google Scholar 

  27. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000.

    Article  CAS  PubMed  Google Scholar 

  28. Benlloch S, Berenguer M. Chronic viral hepatitis. Friedman SL, Keeffe EB, Dienstag JL, editors. Philadelphia: Elselvier Saunders; 2012.

    Chapter  Google Scholar 

  29. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.

    Article  CAS  PubMed  Google Scholar 

  30. Yang HI, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  CAS  PubMed  Google Scholar 

  31. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.

    Article  CAS  PubMed  Google Scholar 

  32. Chen JD, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747–54.

    Article  PubMed  Google Scholar 

  33. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1.

    Article  PubMed  Google Scholar 

  34. Terrault NA, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.

    Article  PubMed  Google Scholar 

  35. Ditah I, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60(4):691–8.

    Article  PubMed  Google Scholar 

  36. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.

    PubMed  Google Scholar 

  38. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1–39.

    Google Scholar 

  39. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–57.

    Article  PubMed  Google Scholar 

  40. Surveillance for Viral Hepatitis – United States, 2014. http://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm. Accessed 18 Aug 2016

  41. Malhi H, Gores GJ. Mechanisms of liver injury. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff’s diseases of the liver. 11th ed. Chichester: John Wiley and Sons; 2012. p. 216–31.

    Google Scholar 

  42. Lemasters JJ. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Phys. 1999;276(1 Pt 1):G1–6.

    CAS  Google Scholar 

  43. Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology. 2005;129(1):351–60.

    Article  PubMed  Google Scholar 

  44. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43(2 Suppl 1):S31–44.

    Article  CAS  PubMed  Google Scholar 

  45. Faouzi S, et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem. 2001;276(52):49077–82.

    Article  CAS  PubMed  Google Scholar 

  46. Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology. 2003;125(4):1246–57.

    Article  CAS  PubMed  Google Scholar 

  47. Ogasawara J, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364(6440):806–9.

    Article  CAS  PubMed  Google Scholar 

  48. Matsumura H, et al. Necrotic death pathway in Fas receptor signaling. J Cell Biol. 2000;151(6):1247–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Trautwein C, et al. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1 Suppl):S15–24.

    Article  CAS  PubMed  Google Scholar 

  50. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830–41.

    Article  CAS  PubMed  Google Scholar 

  52. Iwaisako K, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014;111(32):E3297–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lemoinne S, et al. Origins and functions of liver myofibroblasts. Biochim Biophys Acta. 2013;1832(7):|948–54.

    Article  CAS  PubMed  Google Scholar 

  54. Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.

    Article  CAS  PubMed  Google Scholar 

  55. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.

    Article  CAS  PubMed  Google Scholar 

  56. Jarnagin WR, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol. 1994;127(6 Pt 2):2037–48.

    Article  CAS  PubMed  Google Scholar 

  57. Friedman SL. Hepatic fibrosis: emerging therapies. Dig Dis. 2015;33(4):504–7.

    Article  PubMed  Google Scholar 

  58. Bosch J, et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010;53(3):558–67.

    Article  CAS  PubMed  Google Scholar 

  59. Kawada N, et al. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem. 1993;213(2):815–23.

    Article  CAS  PubMed  Google Scholar 

  60. Kaneda K, et al. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology. 1998;27(3):735–47.

    Article  CAS  PubMed  Google Scholar 

  61. Zhang JX, Pegoli W Jr, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Phys. 1994;266(4 Pt 1):G624–32.

    CAS  Google Scholar 

  62. Gupta TK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28(4):926–31.

    Article  CAS  PubMed  Google Scholar 

  63. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749–61.

    Article  PubMed  Google Scholar 

  64. Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol. 2008;15(5):473–80.

    Article  PubMed  Google Scholar 

  65. Garcia-Tsao G, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–38.

    Article  CAS  PubMed  Google Scholar 

  66. Garcia-Tsao G, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5(3):419–24.

    Article  CAS  PubMed  Google Scholar 

  67. Abraldes JG, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902–8.

    Article  PubMed  Google Scholar 

  68. Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–3.

    Article  PubMed  Google Scholar 

  69. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease. 9th ed. Philadelphia: Saunder Elsevier; 2010.

    Google Scholar 

  70. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107.

    Article  PubMed  Google Scholar 

  71. Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–77.

    Article  CAS  PubMed  Google Scholar 

  72. Planas R, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385–94.

    Article  PubMed  Google Scholar 

  73. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.

    Article  PubMed  Google Scholar 

  74. Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337–42.

    Article  CAS  PubMed  Google Scholar 

  75. Gines P, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–54.

    Article  CAS  PubMed  Google Scholar 

  76. Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27(4):669–74. quiz 675–6

    Article  CAS  PubMed  Google Scholar 

  77. Hung TH, Tsai CC, Hsieh YH. The long-term mortality of spontaneous bacterial peritonitis in cirrhotic patients: a 3-year nationwide cohort study. Turk J Gastroenterol. 2015;26(2):159–62.

    Article  PubMed  Google Scholar 

  78. Follo A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495–501.

    Article  CAS  PubMed  Google Scholar 

  79. Tito L, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8(1):27–31.

    Article  CAS  PubMed  Google Scholar 

  80. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis. 1997;17(3):227–32.

    Article  CAS  PubMed  Google Scholar 

  81. Xiol X, et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology. 1996;23(4):719–23.

    Article  CAS  PubMed  Google Scholar 

  82. D’Amico G, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131(5):1611–24.

    Article  PubMed  Google Scholar 

  83. Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet. 2003;361(9361):952–4.

    Article  PubMed  Google Scholar 

  84. Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.

    Article  PubMed  Google Scholar 

  85. Saunders JB, et al. A 20-year prospective study of cirrhosis. Br Med J. 1981;282(6260):263–6.

    Article  CAS  Google Scholar 

  86. Romero-Gomez M, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96(9):2718–23.

    Article  CAS  PubMed  Google Scholar 

  87. Jepsen P, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82.

    Article  PubMed  Google Scholar 

  88. Coltorti M, et al. Liver cirrhosis in Italy. A multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group. Ital J Gastroenterol. 1991;23(1):42–8.

    CAS  PubMed  Google Scholar 

  89. Bustamante J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890–5.

    Article  CAS  PubMed  Google Scholar 

  90. Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis. 2004;19(3–4):345–9.

    Article  CAS  PubMed  Google Scholar 

  91. Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  CAS  PubMed  Google Scholar 

  92. Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med. 2008;358(22):2378–87.

    Article  CAS  PubMed  Google Scholar 

  93. Zhang XJ, et al. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol. 2003;39(5):724–30.

    Article  CAS  PubMed  Google Scholar 

  94. Rodriguez-Roisin R, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861–80.

    Article  CAS  PubMed  Google Scholar 

  95. Corley DA, et al. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology. 1997;113(2):728–30.

    Article  CAS  PubMed  Google Scholar 

  96. Allgaier HP, et al. Hepato-pulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol. 1995;23(1):102.

    Article  CAS  PubMed  Google Scholar 

  97. Lasch HM, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl. 2001;7(2):147–9.

    Article  CAS  PubMed  Google Scholar 

  98. Riegler JL, et al. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology. 1995;109(3):978–83.

    Article  CAS  PubMed  Google Scholar 

  99. Selim KM, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol. 1998;93(3):455–8.

    Article  CAS  PubMed  Google Scholar 

  100. Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol. 2014;20(45):16996–7010.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Krowka MJ. Hepatopulmonary syndrome: recent literature (1997 to 1999) and implications for liver transplantation. Liver Transpl. 2000;6(4 Suppl 1):S31–5.

    Article  CAS  PubMed  Google Scholar 

  102. Pascasio JM, et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant. 2014;14(6):1391–9.

    Article  CAS  PubMed  Google Scholar 

  103. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363(9419):1461–8.

    Article  PubMed  Google Scholar 

  104. Surani SR, et al. Pulmonary complications of hepatic diseases. World J Gastroenterol. 2016;22(26):6008–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Kochar R, Nevah Rubin MI, Fallon MB. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep. 2011;13(1):34–9.

    Article  PubMed  Google Scholar 

  106. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123(2):562–76.

    Article  PubMed  Google Scholar 

  107. Halank M, et al. Portopulmonary hypertension. J Gastroenterol. 2006;41(9):837–47.

    Article  PubMed  Google Scholar 

  108. Swanson KL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445–53.

    Article  CAS  PubMed  Google Scholar 

  109. Salerno F, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  110. Fede G, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–8.

    Article  PubMed  Google Scholar 

  111. Angeli P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690–7.

    Article  CAS  PubMed  Google Scholar 

  112. Esrailian E, et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742–8.

    Article  CAS  PubMed  Google Scholar 

  113. Alessandria C, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499–505.

    Article  CAS  PubMed  Google Scholar 

  114. Ghosh S, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33(8):1187–93.

    Article  CAS  PubMed  Google Scholar 

  115. Nassar Junior AP, et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Singh V, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–8.

    Article  CAS  PubMed  Google Scholar 

  117. Eason JD, et al. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant. 2008;8(11):2243–51.

    Article  CAS  PubMed  Google Scholar 

  118. Nazar A, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58(1):51–7.

    Article  PubMed  Google Scholar 

  119. Karagiannakis DS, et al. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int. 2014;8(4):588–94.

    Article  PubMed  Google Scholar 

  120. Ruiz-del-Arbol L, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology. 2013;58(5):1732–41.

    Article  CAS  PubMed  Google Scholar 

  121. Cazzaniga M, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Rabie RN, et al. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104(10):2458–66.

    Article  PubMed  Google Scholar 

  123. Chen Y, et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. J Cardiol. 2016;67(2):140–6.

    Article  PubMed  Google Scholar 

  124. Mohamed R, et al. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology. 1996;23(5):1128–34.

    Article  CAS  PubMed  Google Scholar 

  125. Torregrosa M, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68–74.

    Article  PubMed  Google Scholar 

  126. Tsochatzis EA, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–74.

    Article  CAS  PubMed  Google Scholar 

  127. Francoz C, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Amitrano L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736–41.

    Article  PubMed  Google Scholar 

  129. Amitrano L, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–8.

    Article  CAS  PubMed  Google Scholar 

  130. Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61(2):660–7.

    Article  CAS  PubMed  Google Scholar 

  131. Zocco MA, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–9.

    Article  PubMed  Google Scholar 

  132. American Cancer Society. Cancer facts and figures 2016. Atlanta, GA: American Cancer Society; 2016.

    Google Scholar 

  133. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–75.

    Article  PubMed  Google Scholar 

  134. Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;​136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  135. N.A. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751–5.

    Google Scholar 

  136. Andersson KL, et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–24.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed  Google Scholar 

  138. Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and treatment of hepatocellular carcinoma in 2016: standards and developments. Visc Med. 2016;32(2):116–20.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Adhoute X, et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8(17):703–15.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.

    Article  PubMed  Google Scholar 

  141. Bhardwaj N, Perera MT, Silva MA. Current treatment approaches to HCC with a special consideration to transplantation. J Transplant. 2016;2016:7926264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Ripoll C, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8.

    Article  CAS  PubMed  Google Scholar 

  143. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.

    CAS  PubMed  Google Scholar 

  144. Cholongitas E, et al. Systematic review: the model for end-stage liver disease—should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–89.

    Article  CAS  PubMed  Google Scholar 

  145. Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–65.

    Article  PubMed  Google Scholar 

  146. Malinchoc M, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.

    Article  CAS  PubMed  Google Scholar 

  147. Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.

    Article  CAS  PubMed  Google Scholar 

  148. Wiesner RH, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7(7):567–80.

    Article  CAS  PubMed  Google Scholar 

  149. Wiesner R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.

    Article  PubMed  Google Scholar 

  150. Hwang JH, et al. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc. 2014;80(2):221–7.

    Article  PubMed  Google Scholar 

  151. Marcellin P, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.

    Article  CAS  PubMed  Google Scholar 

  152. Xu B, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(2):372–8.

    Article  CAS  PubMed  Google Scholar 

  153. Buti M, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015;9(2):243–50.

    Article  PubMed  Google Scholar 

  154. D’Ambrosio R, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532–43.

    Article  PubMed  Google Scholar 

  155. Hezode C, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656–63.

    Article  CAS  PubMed  Google Scholar 

  156. Falize L, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44(2):472–7.

    Article  PubMed  Google Scholar 

  157. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40(4):646–52.

    Article  CAS  PubMed  Google Scholar 

  158. Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med. 1997;126(9):682–8.

    Article  CAS  PubMed  Google Scholar 

  159. Deniz K, et al. Regression of steatohepatitis-related cirrhosis. Semin Liver Dis. 2015;35(2):199–202.

    Article  PubMed  Google Scholar 

  160. Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we now? Semin Liver Dis. 2016;36(1):87–98.

    Article  CAS  PubMed  Google Scholar 

  161. Chang TT, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.

    Article  CAS  PubMed  Google Scholar 

  162. Dixon LJ, et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012;92(5):713–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Pockros PJ, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46(2):324–9.

    Article  CAS  PubMed  Google Scholar 

  164. Baskin-Bey ES, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2005;288(2):G396–402.

    Article  CAS  PubMed  Google Scholar 

  165. Abu-Elheiga L, et al. Acetyl-CoA carboxylase 2−/− mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. J Biol Chem. 2012;287(15):12578–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  166. Baeck C, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology. 2014;59(3):1060–72.

    Article  CAS  PubMed  Google Scholar 

  167. Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Kisseleva T, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A. 2012;109(24):9448–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Columbia University Medical Center, New York, NY, USA

    Lauren Tal Grinspan MD, PhD

  2. Transplant Initiative, Division of Digestive and Liver Diseases, Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, NY, USA

    Elizabeth C. Verna MD, MS

Authors
  1. Lauren Tal Grinspan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth C. Verna MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth C. Verna MD, MS .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, Columbia University Medical Center, New York, New York, USA

    Gebhard Wagener

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Grinspan, L.T., Verna, E.C. (2018). Chronic Liver Failure and Hepatic Cirrhosis. In: Wagener, G. (eds) Liver Anesthesiology and Critical Care Medicine. Springer, Cham. https://doi.org/10.1007/978-3-319-64298-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64298-7_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64297-0

  • Online ISBN: 978-3-319-64298-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation